The markets opened flat with the Dow slipping 6 points to 16,389 as the economy added fewer than expected jobs in February. Nasdaq rose 5 points to 4357.
On the upside
Smith & Wesson (Nasdaq: SWHC) reported higher fourth quarter earnings and revenue that beat analyst expectations.
Peregrine Pharmaceuticals (Nasdaq: PPHM) announced that three data presentations will discuss the immune-oncology and anti-viral potential of phosphatidylserine-targeting antibodies.
Shares of FuelCell Energy (Nasdaq: FCEL) continued rising.
On the downside
XOMA (Nasdaq: XOMA) will stop testing its arthritis treatment gevokizumab after it failed two mid-stage studies.
Ceres (Nasdaq: CERE) priced its public offering of 20 million common shares at the discounted price of $1.00 per share.
Canadian Solar (Nasdaq: CSIQ) swung to a profit for the fourth quarter but the results fell far short of analyst expectations.
In the broad market, declining issues outpaced advancers by a margin of nearly 5 to 4 on the NYSE and by nearly 3 to 2 on Nasdaq. The broader S&P 500 added 2 points to 1876. Bitcoin eased $2.94 or 0.44% to $659.50.
